Corpus ID: 8365820

Strategies for Dealing with Missing Data in Clinical Trials: From Design to Analysis

@inproceedings{Dziura2013StrategiesFD,
  title={Strategies for Dealing with Missing Data in Clinical Trials: From
Design to Analysis},
  author={James D Dziura and Lori Ann Post and Qing Zhao and Zhixuan Fu and Peter Peduzzi},
  booktitle={The Yale journal of biology and medicine},
  year={2013}
}
Randomized clinical trials are the gold standard for evaluating interventions as randomized assignment equalizes known and unknown characteristics between intervention groups. However, when participants miss visits, the ability to conduct an intent-to-treat analysis and draw conclusions about a causal link is compromised. As guidance to those performing clinical trials, this review is a non-technical overview of the consequences of missing data and a prescription for its treatment beyond the… Expand

Figures from this paper

Paper Mentions

Interventional Clinical Trial
This is a randomized comparative trial investigating two different catheter management strategies among post-gynecologic surgery patients. Women undergoing any benign gynecologic… Expand
ConditionsSatisfaction, Urinary Retention, Urinary Tract Infections
InterventionOther
Interventional Clinical Trial
The purpose of this study is to determine if any difference exists among 3 different postoperative splinting regimens- no splint, removable splint, and plaster non-removable… Expand
ConditionsCarpal Tunnel Syndrome
InterventionOther
Transparent reporting of missing outcome data in clinical trials: applying the general principles of CONSORT 2010
TLDR
There is more need than ever to ensure that clinical trials are reported clearly and include sufficient detail to allow readers to critically assess the underlying assumptions made by investigators. Expand
A guidance was developed to identify participants with missing outcome data in randomized controlled trials.
TLDR
Adopting the proposed guidance on how to identify participants with missing outcome data in reports of RCTs will help promote transparency and consistency regarding how missing data is managed in systematic reviews. Expand
When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts
TLDR
This work considers how to optimise the handling of missing data during the planning stage of a randomised clinical trial and recommends analytical approaches which may prevent bias caused by unavoidable missing data. Expand
Missing data in clinical trials: a different point of view.
TLDR
Considering that in modern clinical research advanced statistical softwares are readily available, sophisticated methods including regression imputation, multiple imputation and maximum likelihood should be the preferred techniques to deal with missing data. Expand
Interpreting Clinical Trial Data
Effective interpretation of clinical trial data allows for the integration of high-quality clinical research into clinical practice. Evidence from clinical trials directly impacts clinical decisionExpand
A systematic survey on reporting and methods for handling missing participant data for continuous outcomes in randomized controlled trials.
TLDR
Most RCTs reporting continuous outcomes reported in 2014 failed to use optimal analytic methods, and very few conducted sensitivity analyses addressing the possible impact of MPD or commented on how MPD might influence risk of bias. Expand
Sensitivity to missing not at random dropout in clinical trials: use and interpretation of the Trimmed Means Estimator
TLDR
An adjusted estimator is proposed, which relaxes the location shift assumption and how the bias formulae can be used to establish the direction of bias of CCA, MI and TM estimates under a range of plausible data scenarios, to inform sensitivity analyses. Expand
A novel complete-case analysis to determine statistical significance between treatments in an intention-to-treat population of randomized clinical trials involving missing data
TLDR
A generalized complete-case (GCC) analysis based on the data of completers reveals that a statistically significant GCC result implies a significant treatment effect in the ITT population at a pre-specified significance level unless, relative to the comparator, the test drug is poisonous to the non-completers as documented in their medical records. Expand
Missing repeated measures data in clinical trials
TLDR
In clinical trials, truly ignorable data are rare, resulting in additional analysis methods required for proper interpretation of the results, and conducting several analyses under different assumptions, called sensitivity analyses, can determine the extent of the impact of the missing data. Expand
A dynamical modeling approach for analysis of longitudinal clinical trials in the presence of missing endpoints
TLDR
A validated mathematical model combined with an inverse problem approach is used to predict the values for the missing endpoints in a small randomized HIV clinical trial. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Prevention of Missing Data in Clinical Research Studies
TLDR
Seven steps to minimizing the amount of missing data are defined as documentation, training, monitoring reports, patient contact, data entry and management, pilot studies, and communication, and the implementation of these approaches is time consuming and costly. Expand
Assessing and interpreting treatment effects in longitudinal clinical trials with missing data
TLDR
It is proposed that, in many settings, the primary efficacy analysis should use a repeated measures, likelihood-based, mixed-effects modeling approach, with LOCF used as a secondary, composite measure of efficacy, safety, and tolerability. Expand
Missing data in randomised controlled trials: a practical guide
TLDR
A principled approach to handling missing data in clinical trials is proposed, and how this principled approach can be practically, and directly, applied to the majority of trials with longitudinal follow-up is outlined. Expand
COMPARISON OF ALTERNATIVE STRATEGIES FOR ANALYSIS OF LONGITUDINAL TRIALS WITH DROPOUTS
TLDR
Application of the various approaches to the analysis of clinical data from a longitudinal trial confirms the underestimation of the variability when the LOCF approach is used. Expand
A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials.
TLDR
The structured sensitivity framework of using a worst reasonable case result based on a controlled imputation approach with transparent and debatable assumptions supplemented a series of plausible alternative models under varying assumptions was useful in this specific situation and holds promise as a generally useful framework. Expand
How much can we learn about missing data?: an exploration of a clinical trial in psychiatry
TLDR
This work uses two sources of ancillary data to explore the missing data mechanism in a trial of adherence therapy in patients with schizophrenia: carer-reported (proxy) outcomes and the number of contact attempts, and performs sensitivity analyses to departures from missingness at random. Expand
A multiple imputation strategy for clinical trials with truncation of patient data.
TLDR
This work proposes an approach based on multiple imputation of theMissing responses, using the approximate Bayesian bootstrap to draw ignorable repeated imputations from the posterior predictive distribution of the missing data, stratifying by a balancing score for the observed responses prior to withdrawal. Expand
The statistician's role in the prevention of missing data.
TLDR
A Human Immunodeficiency Virus (HIV) case study where statisticians led a project to reduce dropouts and the implementation of new retention strategies and efforts within clinical trial teams attests to the influence of the analyses described in this case study. Expand
Statistical considerations in the intent-to-treat principle.
  • J. Lachin
  • Computer Science, Medicine
  • Controlled clinical trials
  • 2000
TLDR
This paper describes some of the statistical considerations in the intent-to-treat design and analysis of clinical trials and describes the potential bias that can be introduced by such postrandomization exclusions and the pursuant effects on type I error probabilities. Expand
ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS
TLDR
Estimates of treatment group differences in mean change from baseline to endpoint from MMRM were, on average, markedly closer to the true value than estimates from LOCF in every scenario simulated. Expand
...
1
2
3
4
5
...